- Home
- SKYE vs AUBN Comparison
SKYE vs AUBN Comparison
Compare SKYE & AUBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- AUBN
- Stock Information
- Founded
- SKYE 2012
- AUBN 1907
- Country
- SKYE United States
- AUBN United States
- Employees
- SKYE N/A
- AUBN N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- AUBN Major Banks
- Sector
- SKYE Health Care
- AUBN Finance
- Exchange
- SKYE Nasdaq
- AUBN Nasdaq
- Market Cap
- SKYE 80.7M
- AUBN 74.7M
- IPO Year
- SKYE N/A
- AUBN 1995
- Fundamental
- Price
- SKYE $2.43
- AUBN $21.36
- Analyst Decision
- SKYE Buy
- AUBN
- Analyst Count
- SKYE 7
- AUBN 0
- Target Price
- SKYE $18.67
- AUBN N/A
- AVG Volume (30 Days)
- SKYE 136.4K
- AUBN 1.7K
- Earning Date
- SKYE 03-21-2025
- AUBN 04-23-2025
- Dividend Yield
- SKYE N/A
- AUBN 5.26%
- EPS Growth
- SKYE N/A
- AUBN 359.14
- EPS
- SKYE N/A
- AUBN 1.83
- Revenue
- SKYE N/A
- AUBN $30,563,000.00
- Revenue This Year
- SKYE N/A
- AUBN N/A
- Revenue Next Year
- SKYE N/A
- AUBN N/A
- P/E Ratio
- SKYE N/A
- AUBN $11.12
- Revenue Growth
- SKYE N/A
- AUBN 31.96
- 52 Week Low
- SKYE $2.31
- AUBN $16.48
- 52 Week High
- SKYE $17.65
- AUBN $25.40
- Technical
- Relative Strength Index (RSI)
- SKYE 40.00
- AUBN 52.86
- Support Level
- SKYE $2.40
- AUBN $21.00
- Resistance Level
- SKYE $2.88
- AUBN $21.48
- Average True Range (ATR)
- SKYE 0.24
- AUBN 0.37
- MACD
- SKYE -0.02
- AUBN 0.03
- Stochastic Oscillator
- SKYE 3.74
- AUBN 78.74
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About AUBN Auburn National Bancorporation Inc.
Auburn National Bancorp Inc operates as a bank holding company, which offers checking, savings, transaction deposit accounts and certificates of deposit, and is an active residential mortgage lender in its primary service area. The Bank's primary service area includes the cities of Auburn and Opelika, Alabama and nearby surrounding areas in East Alabama, predominantly in Lee County. The Bank also offers commercial, financial, agricultural, real estate construction and consumer loan products and other financial services. The Bank also provides automated teller machine (ATM) services in East Alabama and operates ATM machines. The Bank offers Visa Checkcards, which are debit cards. The Bank offers online banking, bill payment and other electronic banking services through its Internet website.